Pulse Biosciences, Inc · NASDAQ:PLSE
Pulse Biosciences — IPO Roadshow (March 2016)
28 slides from Pulse Biosciences's IPO roadshow presentation, Mar 28, 2016
Slide 1: Advancing therapies through cell signaling
Filed Pursuant Advancing Darrin Uecker, therapies to CEO/President Rulethrough 433 Registration cell + Richard signaling Statement Nuccitelli, 333-208694 Ph.D., CSOMarch 28, 2016
Slide 2: Forward-looking Information
Information We relates. and the This “expect,” “should,” successfully assumptions; of Forward?looking inherent obligation, In by Pulse research this companies prospectus have this presentation Biosciences document, Before offering. in filed “intend,” “continue,” our to and Included develop and updat
Slide 3: Pulse Biosciences Overview
NovelFDA Nanosecond Addresses Proprietary Leveraging Dominant Capital U.S. Potential Pulse generator Biosciences therapeutic efficient strategic 510(k) IP multiple position investment Pulsed position platform commercialization for tissue partnerships Overview Confidential potential Electric inthe wi
Slide 4: Unique Cellular Effect of Nanosecond Pulses
Unique Nanosecond The Pulse nanopores Biosciences nsPEFpulses Cellular allow Confidential applied Ca2+ Effect to across flow 4 a+cell -into create the cell, transient stressing nanopores the endoplasmic in the cell reticulum, membraneandandinducing organelles. unique cellular responses.
Slide 5: Modulating Pulse Parameters
Modulating programmed number When induce Applying of pulse tissue This Nano-Pulsed Pulse tissue novel Biosciences ablation. applied immunogenic may the non-thermal the cell Electro-Signaling Electro-Signaling. pulses result toPulse pulses malignant death Confidential in across apoptosis. Modulation
Slide 6: PulseTx System – First Commercial System
Designed Plan Tunable PulseTxTM PulsetoBiosciences submit design to System –support The ais510(k) based is Confidential First Design adeveloping wide for Commercial on asoft array novel 6tissue the ofpulse first electrodes. NPES ablation. tunable generator System NPES architecture. platform for huma
Slide 7: PulseTx Electrode Designs
Cardiac broad Relatively Designs Laparoscopic PulseTxTM Pulse Biosciences array Clamp forsmall of surface Electrodes is Electrode Electrode electrodes. designed incremental Confidential treatments Designs to support investment in 7 open a surgery in electrode and minimally face Electrodes Endoscopic
Slide 8: Pursuing Three Vertical Markets
NPESOncology Pursuing Tissue Published icine Pulse Medicine Biosciences Applications Ablation three data significant validates may Confidential Dermatology the vertical use8ofmarkets: ditional Oncology opportunity. Tissue theseAblation, verticals. Veterinary Oncology, and Dermatology/Aesthetics.
Slide 9: NPES for Tissue Ablation
Current Ablation NPES We Pulse believe Biosciences for induces treatment ablation zones Tissue NPESapoptosis, with times technologies Ablation has Confidential NPES demonstrated arewith short—seconds depend use indicated 9 heat on anthe or ability good cooling electric to several healing to induce t
Slide 10: Tissue Ablation Partnership Strategy
TissueBiosciences Engage Partnership Potential Additional Pulse Ablation strategic applications applications opportunities –partners Partnership Confidential include ininENT lung cardiac Strategy asthma, 10 and ablation GI ablation COPD, specialties applications and may chronic be pursued bronchitis
Slide 11: Cancer Immunotherapy Opportunity
CancerBiosciences Oncology Major Checkpoint Leading PulseTxTM NPES Potentially Pulse biopharma treatment immunotherapy cancer overcomes synergistic inhibitors platform centers may companies Confidential enable may have with many are is revolutionizing play marketing shown other drug-free of investin
Slide 12: Oncology—Immune Response Mechanisms
Oncology—Immune Oncolytic Intratumoral Tumor Adaptive NPES -+ CRT Immune Pulse Cells NPESon Biosciences In-Situ Antigen undergo Cells surface Application response Viral Virus Cell Vaccine Ingestion Immune Adaptive Lysis Confidential must Dendritic Response Immune Dendritic enter Response immunogenic
Slide 13: Oncology – Initial Immune Response Data
Oncology N1-S1 Percent Survival Days NPES 23 Chen Pulse Ratafter et Biosciences Tx Challenge liver NPES al. Proportion –Initial Euro Immune tumors treated JInjections of Confidential were (Immuno-protection) Cancer Response (n=23) ablated, 50:Data 13 2705 seven (2014) weeks later secondary tumors we
Slide 14: Oncology – Immune Response Data
Oncology all injection, – Immune NPES vaccinated Response mice Data resisted Tumor cells tumor treated growth in unless vitro with theyNPES were pre-treated were used towith vaccinate an anti-CD8 mice against antibody. fibrosarcoma Nuccitelli ettumors. al. PLOS Three Oneweeks 10(7):e0134364 post vac
Slide 15: Oncology Go-to-Market and Partnership Plan
Oncology Demonstrate Planning The Several Partnership We Biopharma Pulse believe first Biosciences additional clinical to–companies there opportunities execute Go NPES toapplication are Confidential market applications provides aasmall number involved with study may local, medtech of may 15 inoncolo
Slide 16: Dermatology/Aesthetics Vertical
Dermatology/Aesthetics Current NPES Apoptosis Short In Immune Example Seborrheic Pulse office treatment Biosciences can treatments response treatment ofcan provide Keratosis Single result time potential Confidential athat NPES ofcompelling in and freezing, will complete Vertical we Treatment fit bel
Slide 17: Dermatology/Aesthetics Feasibility Pilot Study
Dermatology/Aesthetics Feasibility Seven No NPES Pilot We May Example multiple BCC Pulse visible believe help study Treatment Biosciences Wart of Basal HPV ten of understand scars demonstrated of the this Pilot Cell lesions up wart study trial in to Study Carcinoma Confidential successfully indicati
Slide 18: Dermatology/Aesthetics Plan
Dermatology/Aesthetics Planning Initial We Pulsebelieve Biosciences regulatory forthe a clinical PulseTx clearance Confidential study will – Go through be intodermatology 18 a Market good the fit straightforward in the in 2016 product to validate FDA portfolios 510(k) treatment ofprocess the large p
Slide 19: Veterinary Commercial Rationale
Commercial Veterinary It there cancer 50% Existing No Medical May Can *U.S. Pulse has regulatory de-bulk of provide are Biosciences been Pet isall Rationale therapies over the (Dog dogs reported tumor Rationale #1 a70 clearance therapy simple and cause will million tend Confidential with Cat) that*,
Slide 20: Veterinary Plan
Veterinary Plan Potentially PulsetoBiosciences execute engage –partner Golarge with studies toConfidential with Market high veterinary atlarge volume major veterinary chains 20 veterinary veterinary todevice assess medicine oncologists or market oncology center(s) feasibility to perform companies to
Slide 21: Intellectual Property Portfolio
Intellectual We Patent 39 41 Current NPES Use Pulse issued pending believe ofBiosciences pulse Portfolio NPES patents worldwide our worldwide Property generators, toNPES and induce Confidential patent IPan cell electrodes, position immune applications apoptosis 21enables response andordescribe indic
Slide 22: Commercialization Strategy
Commercialization Develop File Pilot Pursue Pulsefor studies Biosciences partnerships athe 510(k) first and clearance partnering tunable Confidential Strategy in applications NPES ofpre-510(k) the22 platform, PulseTxTM where clearance. PulseTxTM, strategics Systemhave for to soft domain support tiss
Slide 23: Commercialization Priorities
Commercialization Focus Pulse Biosciences on applications applications/indications Confidential Priorities where there reimbursement 23that are multiple requireislittle not partnering critical to no clinical opportunities (eg. aesthetics studies and andwhere veterinary) our technology could add sign
Slide 24: Experienced Management Team
Darrin 20+ COO Experience Rich Over Past Brian Experienced Dave 15 Pulse years years President Nuccitelli, 35 120 Danitz, of Biosciences Dow, Uecker, Auxogyn, years medical published medical in CFO MedTech VP Surgical experience ofPresident/CEO Ph.D. the of device Management Confidential device CEO/
Slide 25: Senior Board of Directors
Darrin 26 Senior Thierry CEO Former Mitch Founder Robert Co-Founder Co-managed Pulse years Cephea Biosciences Levinson, Uecker, Managing Levande, Greenberg, Director CEO SVP Thaure, & Pfizer CEO Former of Accuray the Endogastric VirnetX Second President/CEO, Medical Director Orthovita Alfred Directo
Slide 26: Overview of Offering
IPOmillion 5,000,000 7.5 Pre-money Requirement Timing Pulse Overview Biosciences of offering shares valuation shares to raise atoutstanding Confidential –$4.00 late future approximately April per capital share pre-offering, early 26 via $30 May rights million; 12.5 offerings million post-money topos
Slide 27: Summary Investment Highlights
Broad Experienced A Capital Multiple Pulse straightforward number Biosciences platform efficient value of team significant inflection technology value 510(k) capable Confidential creation applications milestones—clinical path ofwith developing based plan; 27 a dominant on and to pursue predicate and
Slide 28: Advancing therapies through cell signaling
[Advancing 849 Mittentherapies Road + Suite through 104cell + Burlingame, signaling California 94010 + Tel: 650.697.3939 ]